Speaking of verticals my eyes were opened yesterday to just how important Twitter is in the medical community. Now I’m no doctor and I’ve never played one on TV but I recently started engaging with a radiologist on Twitter who opened my eyes to the growing role Twitter is playing in the medical community. I asked Matt (@MFCovington) if I could share the direct message he sent me as I found it quite fascinating and he’s given me the green light, so here it is below (thanks Matt!):
“This is a fantastic platform. Preferred social network for doctors and a fantastic resource for physicians to network and connect with peers and get up to date, truly relevant info faster than the medical journals. Twitter has become an integral part of many large medical conferences, healthcare tweetchats are common, and the merits of physicians being involved on Twitter is a common theme discussed in medical journals, particularly in my specialty of radiology. LinkedIn doesn’t seem to have this same presence among many physicians. Facebook, Instagram, and the others (does Snapchat even deserve mention here?) are not used as a professional information and networking resource, as is seen with Twitter.”
I remain convinced that Twitter the network has only scratched the surface of its overall potential which is why I plan on holding my shares for quite some time to come. It sounds like Matt is in the same boat thanks to his experience with the platform. Like we always say here, investing is a marathon not a sprint. And while Twitter got off to a slow start it sure seems like strong leadership has the platform and the business headed in the right direction. I assume they know (at least to a degree) about Matt’s perspective here and the role Twitter can and does play in the medical community; in the age of telemedicine and virtual healthcare it seems like an opportunity. If not then consider this my polite “ahem, Jack you may want to take a look at this” moment. So ahem Jack, you may want to take a look at this.
Jason A. Moser
Senior Analyst, The Motley Fool